Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trial

Liver Transplantation

Volumn 15, Issue 10, 2009, Pages 1262-1269

  De Simone, Paolo ^a   Metselaar, Herold J ^b   Fischer, Lutz ^c   Dumortier, Jérôme ^d   Boudjema, Karim ^e   Hardwigsen, Jean ^f   Rostaing, Lionel ^g   De Carlis, Luciano ^h   Saliba, Faouzi ⁱ   Nevens, Frederik ^j  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^f HÔPITAL DE LA CONCEPTION   (France)

^g CHU RANGUEIL   (France)

^h OSPEDALE NIGUARDA CA GRANDA   (Italy)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; EVEROLIMUS; METHYLPREDNISOLONE ACETATE; TACROLIMUS;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BRONCHITIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; DYSPNEA; ECZEMA; ERYTHEMA; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HERPES SIMPLEX; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERSTITIAL LUNG DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG FIBROSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHLEBITIS; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VIRUS LOAD;

EID: 70350563946     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21827     Document Type: Article

References (35)

1. Organ Procurement and Transplant Network. Available at: http://optn.transplant.hrsa.gov/latestData/viewDataReports.asp. Accessed September 2009.
2. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-940. (Pubitemid 37064766)
3. Lebron Gallardo M, Herrera Gutierrez ME, Seller Perez G, Curiel Balsera E, Fernandez Ortega JF, Quesada Garcia G. Risk factors for renal dysfunction in the postoperative course of liver transplant. Liver Transpl 2004;11:1379-1385. (Pubitemid 39530053)
4. Pawarode A, Fine DM, Thuluwath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003;9:741-747. (Pubitemid 36874464)
5. Moreno JM, Cuervas-Mons V, Rubio E, Pons F, Herreros de TA, Turrion VS, et al. Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. Transplant Proc 2003;35:1907-1908. (Pubitemid 37093759)
6. Campbell KM, Yazigi N, Ryckman FC, Alonso M, Tiao G, Balistreri WF, et al. High prevalence of renal dysfunction in long-term survivors after pediatric liver transplantation. J Pediatr 2006;148:475-480.
7. Cantarovich M. Renal dysfunction in liver transplantation: the problem and preventive strategies. Can J Gastroenterol 2004;18(suppl C):27C-40C.
8. Morard I, Mentha G, Spahr L, Majno P, Hadengue A, Huber O, et al. Long-term renal function after liver transplantation is related to calcineurin inhibitors blood levels. Clin Transplant 2006;20:96-101. (Pubitemid 43349033)
9. Schlitt HJ, Barkmann A, Boeker KHW, Schmidt HH, Emmanouilidis N, Rosenau J, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in livertransplant patients with renal dysfunction: a randomized controlled study. Lancet 2001;357:587-591. (Pubitemid 32179611)
10. Orlando G, Baiocchi L, Cardillo A, Iaria G, De Liguori Carino N, De Luca L, et al. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. Liver Transpl 2007;13:46-54. (Pubitemid 46099973)
11. Koch RO, Graziadei IW, Schultz F, Nachbaur K, Konigsrainer A, Margreiter R, et al. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Transpl Int 2004;17:518-524. (Pubitemid 39592738)
12. Detry O, De Roover A, Honore P, Delwaide J, Jacquet N, Meurisse M. Mycophenolate mofetil monotherapy in stable liver transplant recipients with progressive renal failure. Transplant Proc 2002;34:782-783. (Pubitemid 34556802)
13. Garcia CE, Ribeiro HB, Garcia RL, Copstein JL, Padilla JM, Santos TE, et al. Mycophenolate mofetil in stable liver transplant patients with calcineurin inhibitor-induced renal impairment: single-center experience. Transplant Proc 2003;35:1131-11120
14. Heffron TG, Smallwood GA, Davis L, Martinez E, Stieber AC. Sirolimus-based immunosuppressive protocol for calcineurin sparing in liver transplantation. Transplant Proc 2002;34:1522-1523. (Pubitemid 34895214)
15. Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003;9:126-129. (Pubitemid 36204562)
16. Neff GW, Montalbano M, Slapak-Green G, Meyer D, Berney T, Safdar K, et al. Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. Transplant Proc 2003;35:3029-3031. (Pubitemid 38102122)
17. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003;9:1079-1085. (Pubitemid 37304464)
18. Sanchez EQ, Martin AP, Ikegami T, Uemura T, Narasimhan G, Goldstein RM, et al. Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years. Transplant Proc 2005;37:4416-4423. (Pubitemid 43016046)
19. Cotterell AH, Fisher RA, King AL, Gehr TW, Dawson S, Sterling RK, et al. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 2002;16(suppl 7):49-51. (Pubitemid 41185585)
20. Wadei HM, Mai M, Ahsan N, Rosser BG, Gonwa TA. High risk of proteinuria and lack of improvement of kidney function following sirolimus conversion in liver transplant recipients. Am J Transplant 2008;8(suppl 2):A1370.
21. Shaih TA, Sterling RK, Shiffman ML, Fisher RA, Cotterell AH, Maluf DG, et al. Adverse effects and poor tolerance of sirolimus (SIR) in liver transplant (LT) recipients. Am J Transplant 2008;2(suppl 2):A480.
22. Watson CJE, Gimson AES, Alexander GJ, Allison MED, Gibbs P, Smith JC, et al. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2007;13:1694-1702.
23. Shenoy S, Hardinger KL, Crippin J, Desai N, Korenblat K, Lisker-Melman M, et al. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial. Transplantation 2007;83:1389-1392. (Pubitemid 46800318)
24. Sher L, Marotta P, Teperman L, Sebasian A, Moonka D, Koneru B, et al. Spare-the-Nephron (STN) trial in liver transplant recipients: interim efficacy and safety of mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy after CNI withdrawal. Am J Transplant 2008;8(suppl 2):A2.
25. Kovarik JM, Kahan BD, Kaplan B, Lorber M, Winkler M, Rouilly M, et al., for the Everolimus Phase 2 Study Group. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001;69:48-56.
26. Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006;12:1640-1648. (Pubitemid 44742543)
27. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
28. Kovarik JM, Curtis JJ, Hricik DE, Pescovitz MD, Scantlebury V, Vasquez A. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Transplant Proc 2006;38:3456-3458. (Pubitemid 44908476)
29. Brandhorst G, Tenderich G, Zittermann A, Oezpeker C, Koerfer R, Oellerich M, et al. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. Ther Drug Monit 2008;30:113-116. (Pubitemid 351161109)
30. Holdaas H, Bentdal Ø, Pfeffer P, Mjørnstedt L, Solbu D, Midtvedt K. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 2008;22:366-371.
31. Ruiz JC, Sanchez-Fructuoso A, Rodrigo E, Conesa J, Cotorruelo JG, Gómez-Alamillo C, et al. Conversion to everolimus in kidney transplant recipients: a safe and simple procedure. Transplant Proc 2006;38:2424-2426. (Pubitemid 44693742)
32. Sánchez Fructuoso A, Ruiz San Millán JC, Calvo N, Rodrigo E, Moreno MA, Cotorruelo J, et al. Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients. Transplant Proc 2007;39:2148-2150. (Pubitemid 47432693)
33. Morales J, Fierro A, Benavente D, Zehnder C, Ferrario M, Contreras L, et al. Conversion from a calcineurin inhibitor- based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria. Transplant Proc 2007;39:591-593. (Pubitemid 46574809)
34. Rothenburger M, Teerling E, Bruch C, Lehmkuhl H, Suwelack B, Bara C, et al. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. J Heart Lung Transplant 2007;26:250-257. (Pubitemid 46341888)
35. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008;22:1-15. (Pubitemid 351149996)